Caspian Therapeutics
Caspian Therapeutics, Inc.
Caspian is pursuing a potentially disease-modifying approach aimed at restoring the body’s own insulin producing capacity through the selective expansion and improved function of the pancreatic β cells.
caspiantherapeutics.com · San Diego, CA
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$50.0M of $50.0M
Filed2026-09-23
Days since filing10
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- Yes
- Date of first sale
- 2026-09-08
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Robert H. SpencerExecutive Officer
- Troy E. WilsonDirector
- Spike LoyDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged100% sold0.8 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-240
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.